Stage (next event)
Phase 2/3 (Preliminary Data)
Catalyst Info & Data Links
TITLE: Opaganib (ABC294640, Yeliva®) in COVID - Phase 2/3 (Preliminary Data)
ClinicalTrial.gov (NCT04467840): Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
WHAT IS THE CATALYST EVENT?
1. Phase 2/3 Preliminary Data
2. Emergency Use Application
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
1. Q4 2020
2. Q1 2021
08-06-2020 Phase 2/3 COVID-19 Study Approved in Mexico
2020: Compassionate Use of Opaganib For Patients with Severe COVID-19. medRxiv.
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
Opaganib (Yeliva®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities. Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications (Learn more).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post